2. Neuronal Signaling Protein Tyrosine Kinase/RTK Apoptosis
  3. Trk Receptor c-Fms PDGFR Bcr-Abl c-Kit Apoptosis
  4. IHMT-TRK-284

IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC50 values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.

For research use only. We do not sell to patients.

IHMT-TRK-284 Chemical Structure

IHMT-TRK-284 Chemical Structure

CAS No. : 2416844-79-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

IHMT-TRK-284 Related Antibodies

Top Publications Citing Use of Products

View All Trk Receptor Isoform Specific Products:

View All Isoforms
TrkA TrkB TrkC Trk

View All PDGFR Isoform Specific Products:

View All Isoforms
PDGFR PDGFRβ PDGFRα

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC50 values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies[1].

IC50 & Target

TrkB

0.7 nM (IC50)

TrkC

2.6 nM (IC50)

TrkA

10.5 nM (IC50)

CSF1R

1.2 nM (IC50)

PDGFRα

24.2 nM (IC50)

PDGFRβ

95.7 nM (IC50)

Abl1

83.6 nM (IC50)

KIT

2167 nM (IC50)

Cellular Effect
Cell Line Type Value Description References
BaF3 GI50
1.4 μM
Compound: 34
Antiproliferative activity in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
Antiproliferative activity in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
[PMID: 32949955]
In Vitro

IHMT-TRK-284 (Compound 34) (0-10 µM, 72 h) shows antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells[1].
IHMT-TRK-284 (0-10 µM, 24 h) induces apoptosis and arrests the cell cycle into G0/G1 phase in KM-12-LUC cells[1].
IHMT-TRK-284 exerts its inhibitory effect to the colon cancer cells through on-target inhibition of TRK[1].
IHMT-TRK-284 could overcome drug resistant mutants including V573M and F589L in the ATP binding pocket as well as G667C/S in the DFG region[1].
IHMT-TRK-284 shows selectivity over VEGFR2 kinase[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IHMT-TRK-284 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells
Concentration: 0-10 µM
Incubation Time: 72 h
Result: Showed antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells. GI50 for KM-12-LUC cells was 0.002 µM.
Antiproliferative effects of IHMT-TRK-284 against a panel of kinase transformed BaF3 cells[1].
Target BaF3-TEL-ABL BaF3-TEL-CSF1R BaF3-TEL-KIT BaF3-TEL-PDGFRα BaF3-TEL-PDGFRβ BaF3-TEL-TRKA BaF3-TEL-TRKB BaF3-TEL-TRKC
GI50 (nM) 411.1 4 923.2 1.7 1.4 8.5 8.2 27.3

Antiproliferative effects of IHMT-TRK-284 against a panel of TRKs wt/mutants transformed BaF3 cells (n = 3)[1].
Showed antiproliferative effects with GI50s of 1.4 ± 0.011, 0.007 ± 0.001, 0.003 ± 0.001, 0.004 ± 0.001, 0.194 ± 0.013, 0.034 ± 0.002, 0.002 ± 0.001 μM against BaF3, BaF3-LMNA-TRKA, BaF3-LMNA-TRKA-V573M, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G595R, BaF3-LMNA-TRKA-G667C, BaF3-LMNA-TRKA-G667S cells, respectively.

Western Blot Analysis[1]

Cell Line: BaF3-TEL-TRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNATRKA-V573M, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G595R, BaF3-LMNA-TRKA-G667C/S, and KM-12-LUC cells
Concentration: 0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time: 2 h
Result: In transformed BaF3 cells: Inhibited the phosphorylation of TRKA Y490 (EC50 = 0.026 µM) and corresponding tyrosine residues TRKB Y515 (EC50 = 0.069 µM) and TRKC Y516 (EC50 = 0.029 µM); potently inhibited the phosphorylation of Y490 in V573M, F589L, and G667C/S mutants with EC50s of 0.013 µM, 0.021 µM, 0.067 µM, and 0.074 µM respectively. In KM-12-LUC cells: Blocked the phosphorylation of TRKA Y490 at the concentration of 0.01 µM; remarkably inhibited the phosphorylation of downstream signaling mediators AKT T308/S473 and ERK1/2 (T202/Y204) (EC50 less than 0.03 µM).

Apoptosis Analysis[1]

Cell Line: KM-12-LUC cells
Concentration: 0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time: 24 h
Result: Induced dose-dependent cell apoptotic death.

Cell Cycle Analysis[1]

Cell Line: KM-12-LUC cells
Concentration: 0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time: 24 h
Result: Arrested the cell cycle into G0/G1 phase.
In Vivo

IHMT-TRK-284 (Compound 34) (40 and 80 mg/kg; p.o.; daily, 10 days) shows good in vivo PK and antitumor efficacy properties[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Four-week old female nu/nu mice, one million BaF3-TELTRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G667S, and five million KM-12-LUC cells in DMEM medium were formulated as a 1:1 mixture with matrigel and injected into the subcutaneous space on the right flank of nu/nu mice[1]
Dosage: 40 mg/kg and 80 mg/kg
Administration: Daily oral gavage, 10 days
Result: Dose-dependently inhibited the BaF3-TEL-TRKA, BaF3-TEL-TRKB, and BaF3-TEL-TRKC tumor progression with TGI (tumor growth inhibition) of 68%, 93%, and 58%. Dose-dependently inhibited the tumor progression and exhibited the TGI of 93% at 40 mg/kg/day and 95% at 80 mg/kg/day in KM-12-LUC cells inoculated xenograft mouse model. Potently inhibited the tumor growth with TGI values of 88% and 89% respectively at 80 mg/kg dosage in BaF3- LMNA-TRKA-F589L and BaF3-LMNA-TRKA-G667S cells.
Animal Model: Mice, sprague dawley rats, and beagle dogs[1]
Dosage: 1 mg/kg and 10 mg/kg
Administration: Intravenous injection and oral administration (Pharmacokinetic Analysis)
Result: Pharmacokinetic study of IHMT-TRK-284 in mice, sprague dawley rats, and beagle dogsa[1]
Parameter Mice
i.v. (1 mg/kg)		 Mice
p.o. (10 mg/kg)		 Rats
i.v. (1 mg/kg)		 Rats
p.o. (10 mg/kg)		 Beagle Dogs
i.v. (1 mg/kg)		 Beagle Dogs
p.o. (10 mg/kg)
AUC(0-t)
(ng/mL*h)		 748 1431 393 952 323 464
Tmax (h) 0.033 1.5 0.03 4.7 0.08 4.3
T1/2 (h) 2.6 3.4 2.7 2.5 0.03 11.8
Vz (mL/kg) 4934 31567 9682
Molecular Weight

473.59

Formula

C25H27N7OS
CAS No.
SMILES

O=C(NC1=NC(C)=C(C2=CC3=C(C=C2)C(/C=C/C4=NC=CC=C4)=NN3)S1)CN5CCN(C)CC5
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IHMT-TRK-284 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IHMT-TRK-2842416844-79-4Trk Receptorc-FmsPDGFRBcr-Ablc-KitApoptosisTropomyosin related kinase receptor CSF-1 receptorcolony stimulating factor 1 receptorCSF-1RCSF1RPlatelet-derived growth factor receptorSCFRCD117SelectivityAntitumorBaF3KM-12-LUCInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IHMT-TRK-284
Cat. No.:
HY-146697
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.